Literature DB >> 1774502

[Usefulness of ulinastatin as a radical scavenger for protection of reperfusion injury after myocardial ischemia in open heart surgery].

T Kawai1, Y Wada, K Nishiyama, Y Kanki, K Ohga, T Oka, M Yasuda, T Yoshikawa.   

Abstract

The usefulness of ulinastatin for protection of reperfusion injury after myocardial ischemia was evaluated in 25 patients undergone open heart surgery (18 cases with coronary artery bypass grafting and 7 with valve replacements). Twenty five patients were divided into two groups; U (+)-group consisted of 12 patients with ulinastatin (10,000 IU/kg) injected via the aortic root just before aortic declamping, and U (-)-group of 13 patients without ulinastatin. There were no significant differences between the two groups in age, body weight, total cardiopulmonary bypass (CPB) time, and aortic cross clamp time. Blood samples were obtained from coronary sinus before the start of CPB, just before the aortic cross clamp and immediately after reperfusion, and 1 and 3 hours later. Levels of thiobarbituric acid (TBA), alpha-tocopherol (alpha TOC), polymorphonuclear elastase (PMNE), creatine phosphokinase (CK) and creatine phosphokinase isoenzyme (CK-WB) release were measured, and myocardial aerobic metabolism was also evaluated. At each time point after reperfusion, TBA levels in U (+)-group were significantly less (p less than 0.05), and alpha TOC levels were significantly higher (p less than 0.05) than those in U (-)-group. PMNE increased progressively during CPB and showed a peak at 3 hours after reperfusion. And both groups showed increased lactate production and anaerobic metabolism immediately after reperfusion and 1 hour later, as evidenced by changes in excess lactate and redox potential of lactate and pyruvate. There was, however, no significant difference between the two groups with CK-MB as well as CK release.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774502

Source DB:  PubMed          Journal:  Nihon Kyobu Geka Gakkai Zasshi        ISSN: 0369-4739


  4 in total

1.  Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokines and postoperative organ injury.

Authors:  Y Sato; S Ishikawa; A Otaki; T Takahashi; Y Hasegawa; M Suzuki; T Yamagishi; Y Morishita
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-07

2.  Pharmacological intervention for renal protection during cardiopulmonary bypass.

Authors:  K Hashimoto; K Nomura; M Nakano; T Sasaki; H Kurosawa
Journal:  Heart Vessels       Date:  1993       Impact factor: 2.037

3.  Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass.

Authors:  Se-Young Oh; Jong Chan Kim; Yong Seon Choi; Woo Kyung Lee; Yeong-Kyu Lee; Young Lan Kwak
Journal:  Korean J Anesthesiol       Date:  2012-02-20

Review 4.  Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.

Authors:  Qiu-Lan He; Fei Zhong; Fang Ye; Ming Wei; Wei-Feng Liu; Mei-Na Li; Qiao-Bo Li; Wen-Qi Huang; Lai-Bao Sun; Hai-Hua Shu
Journal:  Biomed Res Int       Date:  2014-03-09       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.